<DOC>
	<DOCNO>NCT01106833</DOCNO>
	<brief_summary>This study design combined Phase II/III , randomize , open label , multicenter , prospective comparative study sirolimus plus prednisone versus sirolimus/calcineurin-inhibitor plus prednisone treatment chronic GVHD . Patients stratify transplant center randomize experimental arm one two pre-specified experimental arm ( sirolimus + prednisone comparator arm sirolimus + calcineurin inhibitor + prednisone ) 1:1 ratio .</brief_summary>
	<brief_title>Chronic Graft-versus-Host Disease Treatment ( BMT CTN 0801 )</brief_title>
	<detailed_description>Background : Chronic GVHD medical condition become serious . Chronic GVHD common development allogeneic transplant occur donor cell attack damage tissue . The primary purpose study compare treatment regimen contain sirolimus without calcineurin inhibitor comparator regimen sirolimus calcineurin inhibitor evaluate well chronic GVHD respond treatment . The combination medication study : - Sirolimus + calcineurin inhibitor + prednisone - Sirolimus + prednisone The goal select treatment regimen comparison Phase III trial . Design Narrative : The intent enroll subject start initial therapy chronic GVHD , chronic GVHD refractory glucocorticoid therapy , chronically dependent upon glucocorticoid therapy multiple secondary systemic immunosuppressive agent . Patients stratify transplant center randomize one two arm .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Suitable candidate patient classic chronic GVHD overlap syndrome ( classic chronic plus acute GVHD ) : ) Previously untreated ( newly diagnose ) define receive &lt; 14 day prednisone ( equivalent ) enrollment/randomization study therapy ; b ) Previously treat inadequately respond ≤ 16 week initial therapy prednisone and/or calcineurin inhibitor ( CNI ) ± additional nonsirolimus agent ( started time chronic GVHD diagnosis ) . Patient guardian willing able provide inform consent . Stated willingness use contraception woman childbearing potential . Stated willingness patient comply study procedure report requirement . Patients late persistent acute GVHD recurrent acute GVHD . Inability begin prednisone therapy dose great 0.5 mg/kg/day . Receiving sirolimus treatment chronic GVHD ( sirolimus prophylaxis treatment acute GVHD acceptable ) . Already receive sirolimus ( prophylaxis treatment acute GVHD ) prednisone ≥ 0.25 mg/kg/day ( equivalent ) ± additional agent . Receiving therapy chronic GVHD 16 week . Invasive fungal viral infection respond appropriate antifungal antiviral therapy . Inadequate renal function define measure creatinine clearance le 50 mL/min/1.73 m^2 base CockcroftGault formula ( adult ) Schwartz formula ( age less equal 12 year ) . Adults : estimate creatinine clearance rate ( eCCr ) ( mL/min/ ) = ( 140 age ) x mass ( kg ) x ( 0.85 female ) /72 x serum creatinine ( mg/dL ; Creatinine clearance ( mL/min/1.73m^2 ) = eCCr x 1.73/Body Surface Area ( BSA ) ( m^2 ) ; Children : eCCr ( mL/min/1.73 m^2 ) = k x height ( cm ) / serum creatinine ( mg/dL ) k = 0.33 ( preterm ) , 0.45 ( full term 1 year old ) , 0.55 ( age 112 year ) . Inability tolerate oral medication . Absolute neutrophil count less 1500 per microliter . Requirement platelet transfusion . Pregnancy ( positive serum βHCG ) breastfeeding . Receiving treatment persistent , progressive recurrent malignancy . Progressive recurrent malignancy define quantitative molecular assay . Known hypersensitivity sirolimus .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic Graft-versus-Host Disease ( cGVHD )</keyword>
</DOC>